Determinants of bone specific metastasis in prostate cancer.
Prostate cancer is one of the most common type of cancer in Western countries. Although the majority of patients with PCa have a minimally aggressive disease, some of them will experience relapse and formation of metastasis. Bone metastasis are a major cause of quality of life impairment and death among patients with metastatic prostate cancer. Different "bone targeted therapies" and several follow-up strategies were developed in order to optimize bone metastasis prevention and treatment. Nevertheless there is still a great clinical need of identifying patients more likely to benefit from those interventions as not all patients will develop metastatic disease and not all patients with metastatic disease will develop bone metastasis. Here we review markers predictive of bone metastasis occurrence that have been tested in clinical settings, particularly focusing on the ability of such markers to predict bone metastasis over visceral metastasis occurrence.
Medical Oncology Department, Campus Bio-Medico University, Via Alvaro del Portillo 200, 00128 Rome, Italy. Electronic address: mancapaolo@outlook.it.
Paolo
P
Manca
Medical Oncology Department, Campus Bio-Medico University, Via Alvaro del Portillo 200, 00128 Rome, Italy. Electronic address: f.pantano@unicampus.it.
Francesco
F
Pantano
Medical Oncology Department, Campus Bio-Medico University, Via Alvaro del Portillo 200, 00128 Rome, Italy. Electronic address: m.iuliani@unicampus.it.
Michele
M
Iuliani
Medical Oncology Department, Campus Bio-Medico University, Via Alvaro del Portillo 200, 00128 Rome, Italy. Electronic address: g.ribelli@unicampus.it.
Giulia
G
Ribelli
Medical Oncology Department, Campus Bio-Medico University, Via Alvaro del Portillo 200, 00128 Rome, Italy. Electronic address: d.delisi@unicampus.it.
Delia
D
De Lisi
Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Electronic address: romano.danesi@unipi.it.
Romano
R
Danesi
Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Electronic address: marzia.delre@gmail.it.
Marzia
M
Del Re
Medical Oncology Department, Campus Bio-Medico University, Via Alvaro del Portillo 200, 00128 Rome, Italy. Electronic address: b.vincenzi@unicampus.it.
Bruno
B
Vincenzi
Medical Oncology Department, Campus Bio-Medico University, Via Alvaro del Portillo 200, 00128 Rome, Italy. Electronic address: g.tonini@unicampus.it.
Giuseppe
G
Tonini
Medical Oncology Department, Campus Bio-Medico University, Via Alvaro del Portillo 200, 00128 Rome, Italy. Electronic address: d.santini@unicampus.it.
Daniele
D
Santini
D014408:Biomarkers, Tumor / Q000032:analysis; D001859:Bone Neoplasms / Q000556:secondary*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000473:pathology*
D014408:Biomarkers, Tumor
Bone metastasis prediction; Predictive markers; Prostate cancer